Literature DB >> 25083418

Benefit of tamoxifen in estrogen receptor positive DCIS of the breast.

Petrelli Fausto1, Sandro Barni1.   

Abstract

Entities:  

Year:  2012        PMID： 25083418      PMCID： PMC4115708          DOI： 10.3978/j.issn.2227-684X.2012.04.03

Source DB:  PubMed          Journal:  Gland Surg        ISSN： 2227-684X


× No keyword cloud information.
  7 in total

Review 1.  Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California/Van Nuys Prognostic Index.

Authors:  Melvin J Silverstein; Michael D Lagios
Journal:  J Natl Cancer Inst Monogr       Date:  2010

Review 2.  Network meta-analysis of margin threshold for women with ductal carcinoma in situ.

Authors:  Shi-Yi Wang; Haitao Chu; Tatyana Shamliyan; Hawre Jalal; Karen M Kuntz; Robert L Kane; Beth A Virnig
Journal:  J Natl Cancer Inst       Date:  2012-03-22       Impact factor: 13.506

3.  Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

Authors:  D Craig Allred; Stewart J Anderson; Soonmyung Paik; D Lawrence Wickerham; Iris D Nagtegaal; Sandra M Swain; Elefetherios P Mamounas; Thomas B Julian; Charles E Geyer; Joseph P Costantino; Stephanie R Land; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

4.  Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials.

Authors:  Fausto Petrelli; Sandro Barni
Journal:  Radiother Oncol       Date:  2011-03-14       Impact factor: 6.280

5.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

Authors:  Irene L Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Stewart J Anderson; Thomas B Julian; Stephanie R Land; Richard G Margolese; Sandra M Swain; Joseph P Costantino; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2011-03-11       Impact factor: 13.506

6.  The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast.

Authors:  Melvin J Silverstein
Journal:  Am J Surg       Date:  2003-10       Impact factor: 2.565

7.  Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.

Authors:  Jack Cuzick; Ivana Sestak; Sarah E Pinder; Ian O Ellis; Sharon Forsyth; Nigel J Bundred; John F Forbes; Hugh Bishop; Ian S Fentiman; William D George
Journal:  Lancet Oncol       Date:  2010-12-07       Impact factor: 41.316
  7 in total
  3 in total

1.  Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.

Authors:  Hailing Liu; Yan Wang; Xin Li; Yan-jun Zhang; Jie Li; Yi-qiong Zheng; Mei Liu; Xin Song; Xi-ru Li
Journal:  Tumour Biol       Date:  2013-02-22

2.  miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN.

Authors:  Hong Fang; Jiping Xie; Min Zhang; Ziwei Zhao; Yi Wan; Yongqiang Yao
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

3.  MicroRNA-182 promotes proliferation and metastasis by targeting FOXF2 in triple-negative breast cancer.

Authors:  Xingzeng Zhang; Genshun Ma; Jianchao Liu; Yajun Zhang
Journal:  Oncol Lett       Date:  2017-08-21       Impact factor: 2.967
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.